Co-founder and Chief Scientific Officer Malcolm Meyn is the Chief Scientific Officer of Amalgent Therapeutics.Malcolm began his career as an academic scientist researching the complex systems that regulate how cells and organisms respond to chemical signals. In 2011, he took his skills to industry and began to focus on developing biologic and small drug therapeutics. At Amalgent Therapeutics, Malcolm oversees all research and development programs, supports business development, assists in strategic decision making, and sits on the Board of Directors. www.linkedin.com/in/mameyn/
Co-founder and non-executive ChairSam is Founder and CEO of Grant Engine, a technology consulting firm focused on providing grant writing and other advisory services to university-based inventors and entrepreneurs. He identified the opportunity at Amalgent with Malcolm, and began the Company in 2020. Sam is an active angel investor and member of RTP Capital and Carolina Angel Network.
This opioid adjuvant technology being commercialized at Amalgent was invented by Dr. Kori Brewer and Dr. Stefan Clemens at East Carolina University in Greenville, NC. At ECU, Dr. Brewer is the Associate Chief, Division of Research in the Department of Emergency Medicine and Dr. Clemens is Associate Professor of Physiology. Amalgent is privileged to have continued input from the ECU team as we work to bring the technology to market.